NOVO NORDISK A S (NVO)
A+
Pipeline Grade
Drug Pipeline (7 Assets)
| Drug | Phase | Indications |
|---|---|---|
|
SEMAGLUTIDE
RYBELSUS |
APPROVED | Acquired Bleeding Disorder, Adult Growth Hormone Deficiency, Binge-Eating Disorder, Chronic Kidney Disease, Congenital Bleeding Disorder, Congenital FXIII Deficiency, Diabetes, Diabetes Mellitus, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Diabetic Glomerulosclerosis, Diabetic Nephropathies, End Stage Renal Disease, Genetic Disorder, Gestational Diabetes, Growth Disorder, Growth Hormone Deficiency in Children, Growth Hormone Disorder, Growth Hormone-Deficiency, Haemophilia A, Haemophilia A With Inhibitors, Haemophilia B, Haemophilia B With Inhibitors, Healthy, Healthy Participants, Healthy Volunteers, Heart Failure, Hepatic Steatosis, Inflammation, Intracerebral Haemorrhage, Metabolic Dysfunction-associated Steatohepatitis (MASH), Metabolism and Nutrition Disorder, Monogenic Obesity, Mood Disorders, Non-alcoholic Fatty Liver Disease (NAFLD), Non-alcoholic Steatohepatitis (NASH), Non-muscle Invasive Bladder Cancer, Obesity, Overweight, Psoriasis, Rheumatoid Arthritis, Severe Postpartum Haemorrhage, S |
|
INSULIN DEGLUDEC, LIRAGLUTIDE
XULTOPHY 100/3.6 |
APPROVED | — |
|
LIRAGLUTIDE
SAXENDA |
APPROVED | — |
|
INSULIN DEGLUDEC
TRESIBA |
APPROVED | — |
|
INSULIN ASPART
FIASP FLEXTOUCH |
APPROVED | — |
|
NEDOSIRAN SODIUM
RIVFLOZA |
APPROVED | — |
|
INSULIN ASPART, INSULIN DEGLUDEC
RYZODEG 70/30 |
NDA | — |
Upcoming Catalysts
No upcoming catalysts detected for this company.